Phase 2
Completed N=30
A Study Evaluating the Safety, Tolerability, and Efficacy of EVO756 in Adults With Chronic Inducible Urticaria
Source: ClinicalTrials.gov NCT06603220 ↗Enrolled (actual)
30
Serious AEs
0.0%
Results posted
May 2026
Primary outcomePrimary: Safety and Tolerability — 3; 7 Participants with a TEAE
Summary
This phase 2a trial will evaluate the safety and efficacy of EVO756 in subjects with chronic inducible urticaria, including symptomatic dermographism and cold urticaria.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Safety and Tolerability |
3; 7 | — |
| SECONDARY Change in Total Fric Score (TFS) |
-1.4; -1.5 | — |
| SECONDARY Change in Pruritus Severity at the Provocation Test Site |
-2.4; -2.1 | — |
Eligibility Criteria
Inclusion Criteria
- Confirmed diagnosis of chronic inducible urticaria for at least 3 months.
- Positive response following provocation using the TempTest or FricTest at Screening and Day 1.
Exclusion Criteria
- History of diseases other than chronic inducible urticaria or chronic spontaneous urticaria with urticaria or angioedema symptoms, such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa), and hereditary or acquired angioedema.
- Concurrent use of certain medications, including antihistamines.
- Any clinically significant disease, or other skin disease or skin markings (e.g., extensive scarring, tattoos), that might confound the evaluation of safety or efficacy.
Data sourced from ClinicalTrials.gov (NCT06603220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.